What's Happening?
Moderna has secured a joint procurement contract with the European Commission for its respiratory syncytial virus (RSV) vaccine, mResvia. The contract, requested by six European countries, allows access to up to 24 million doses over four years. This
development comes as Moderna's mResvia faces stiff competition from GSK and Pfizer, whose RSV vaccines have achieved higher sales. The contract aims to bolster RSV vaccination efforts in Europe, particularly for adults, to reduce the burden on healthcare systems during the winter months.
Why It's Important?
The contract represents a significant opportunity for Moderna to expand its market presence in the RSV vaccine sector, which is dominated by competitors. RSV is a common respiratory virus that poses serious risks to older adults and those with underlying health conditions. By increasing access to vaccines, the EU aims to mitigate the impact of RSV on healthcare services and reduce antibiotic use. This contract highlights the importance of international collaboration in addressing public health challenges and supporting vaccine distribution.
What's Next?
Moderna will work with the participating European countries to distribute the mResvia vaccine ahead of the 2026-2027 RSV season. The company will focus on increasing production and ensuring timely delivery of doses. The EU's support for mResvia contrasts with the situation in the U.S., where funding for mRNA vaccine programs has been reduced. Moderna's success in Europe could influence future vaccine procurement strategies and highlight the role of mRNA technology in addressing infectious diseases.
